EA201391399A1 - Макроциклическое соединение и способы его получения - Google Patents

Макроциклическое соединение и способы его получения

Info

Publication number
EA201391399A1
EA201391399A1 EA201391399A EA201391399A EA201391399A1 EA 201391399 A1 EA201391399 A1 EA 201391399A1 EA 201391399 A EA201391399 A EA 201391399A EA 201391399 A EA201391399 A EA 201391399A EA 201391399 A1 EA201391399 A1 EA 201391399A1
Authority
EA
Eurasian Patent Office
Prior art keywords
preparation
methods
macrocyclic compound
compound
macrocyclic
Prior art date
Application number
EA201391399A
Other languages
English (en)
Other versions
EA023848B1 (ru
Inventor
Стивен Джеймс Мосс
Мэттью Алан Грегори
Барри Уилкинсон
Original Assignee
Ньюроувив Фармасьютикал Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105293.3A external-priority patent/GB201105293D0/en
Priority claimed from GBGB1113629.8A external-priority patent/GB201113629D0/en
Priority claimed from GBGB1202060.8A external-priority patent/GB201202060D0/en
Application filed by Ньюроувив Фармасьютикал Аб filed Critical Ньюроувив Фармасьютикал Аб
Publication of EA201391399A1 publication Critical patent/EA201391399A1/ru
Publication of EA023848B1 publication Critical patent/EA023848B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/061,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Представлено, помимо прочего, соединение формулы (I) для применения при лечении вирусной инфекции или в качестве иммуносупрессора.
EA201391399A 2011-03-29 2012-03-29 Макроциклическое соединение и способы его получения EA023848B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1105293.3A GB201105293D0 (en) 2011-03-29 2011-03-29 Novel compounds and methods for their production
GBGB1113629.8A GB201113629D0 (en) 2011-08-08 2011-08-08 Novel compounds and methods for their production
GBGB1202060.8A GB201202060D0 (en) 2012-02-07 2012-02-07 Novel compounds and methods for their production
PCT/GB2012/050700 WO2012131371A1 (en) 2011-03-29 2012-03-29 Macrocyclic compound and methods for its production

Publications (2)

Publication Number Publication Date
EA201391399A1 true EA201391399A1 (ru) 2014-02-28
EA023848B1 EA023848B1 (ru) 2016-07-29

Family

ID=46001313

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201391396A EA023907B1 (ru) 2011-03-29 2012-03-29 Макроциклические соединения и способы их получения
EA201391399A EA023848B1 (ru) 2011-03-29 2012-03-29 Макроциклическое соединение и способы его получения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201391396A EA023907B1 (ru) 2011-03-29 2012-03-29 Макроциклические соединения и способы их получения

Country Status (29)

Country Link
US (2) US9139613B2 (ru)
EP (2) EP2691413B1 (ru)
JP (2) JP6118792B2 (ru)
KR (2) KR101911484B1 (ru)
CN (3) CN107417766A (ru)
AR (1) AR085724A1 (ru)
AU (2) AU2012235961B2 (ru)
BR (2) BR112013024974A2 (ru)
CA (2) CA2830831C (ru)
CL (2) CL2013002739A1 (ru)
CY (2) CY1116318T1 (ru)
DK (2) DK2691413T3 (ru)
EA (2) EA023907B1 (ru)
ES (2) ES2533438T3 (ru)
HK (2) HK1189237A1 (ru)
HR (2) HRP20150187T1 (ru)
IL (2) IL228508B (ru)
JO (1) JO3063B1 (ru)
MX (2) MX345351B (ru)
MY (2) MY170637A (ru)
PL (2) PL2691412T3 (ru)
PT (2) PT2691412E (ru)
RS (2) RS53963B1 (ru)
SG (2) SG193568A1 (ru)
SI (2) SI2691413T1 (ru)
TW (1) TWI525098B (ru)
UY (1) UY33993A (ru)
WO (2) WO2012131377A1 (ru)
ZA (2) ZA201307149B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012019866A8 (pt) 2010-02-09 2017-12-26 Biotica Tech Limited Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
CN103130734A (zh) * 2011-12-01 2013-06-05 上海药明康德新药开发有限公司 一种合成1,2-吗啉盐酸盐的方法
CN105695541B (zh) * 2016-03-10 2019-03-15 苏州华赛生物工程技术有限公司 一种抗生素nvp018中间体的分离纯化方法
KR20180036522A (ko) 2016-09-30 2018-04-09 (주)나노믹스 스틸벤 유도체 및 그 제조 방법
BR112019009903A2 (pt) * 2016-11-18 2019-08-13 Neurovive Pharmaceutical Ab análogo de sangliferina, combinação, composição farmacêutica, e, método para tratamento de um sujeito sofrendo de câncer ou de malignidade de célula-b
CN112410353B (zh) * 2019-08-23 2023-01-24 上海医药工业研究院 一种fkbS基因、含其的基因工程菌及其制备方法和用途
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
AR054778A1 (es) * 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
CA2674296C (en) 2007-01-04 2015-11-24 Debiopharm Sa Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
JP5789190B2 (ja) 2008-09-24 2015-10-07 シャンハイ インスティテュート オブ オーガニック ケミストリー,チャイニーズ アカデミー オブ サイエンシズ 新規の遺伝子クラスター
CN101691575B (zh) * 2008-09-24 2013-06-05 中国科学院上海有机化学研究所 一种萨菲菌素的生物合成基因簇
BR112012019866A8 (pt) * 2010-02-09 2017-12-26 Biotica Tech Limited Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
WO2011098808A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098805A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
EP2654753B1 (en) * 2010-12-20 2018-10-31 Neurovive Pharmaceutical AB Sanglifehrin derivatives and methods for their production
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه

Also Published As

Publication number Publication date
RS53963B1 (en) 2015-08-31
EP2691412A1 (en) 2014-02-05
AU2012235880A1 (en) 2013-10-17
MX2013011043A (es) 2014-04-25
CN103619869B (zh) 2015-11-25
CN103635484A (zh) 2014-03-12
HK1189236A1 (en) 2014-05-30
DK2691412T3 (en) 2015-04-07
CL2013002739A1 (es) 2014-07-11
ES2533437T3 (es) 2015-04-10
IL228509B (en) 2018-02-28
KR101911484B1 (ko) 2018-10-24
MX2013011051A (es) 2014-03-13
IL228508A0 (en) 2013-12-31
JP6118793B2 (ja) 2017-04-26
UY33993A (es) 2012-10-31
CA2830827A1 (en) 2012-10-04
AU2012235961B2 (en) 2016-09-01
IL228508B (en) 2018-01-31
US20120251581A1 (en) 2012-10-04
PT2691413E (pt) 2015-03-25
PT2691412E (pt) 2015-03-25
HK1189237A1 (en) 2014-05-30
EP2691413B1 (en) 2014-12-24
CL2013002740A1 (es) 2014-07-11
BR112013024974A2 (pt) 2016-09-06
CY1116318T1 (el) 2017-02-08
MY170618A (en) 2019-08-21
MX345352B (es) 2017-01-26
JP2014510746A (ja) 2014-05-01
ZA201307149B (en) 2015-04-29
AR085724A1 (es) 2013-10-23
CY1116186T1 (el) 2017-02-08
WO2012131371A1 (en) 2012-10-04
CN103635484B (zh) 2017-05-10
EA023848B1 (ru) 2016-07-29
TWI525098B (zh) 2016-03-11
CA2830827C (en) 2020-03-10
DK2691413T3 (en) 2015-04-07
US9139613B2 (en) 2015-09-22
JP6118792B2 (ja) 2017-04-26
SI2691412T1 (sl) 2015-05-29
EP2691412B1 (en) 2014-12-24
SI2691413T1 (sl) 2015-05-29
US20140038885A1 (en) 2014-02-06
CN107417766A (zh) 2017-12-01
IL228509A0 (en) 2013-12-31
SG193568A1 (en) 2013-11-29
BR112013024965A2 (pt) 2017-04-18
WO2012131377A1 (en) 2012-10-04
HRP20150187T1 (en) 2015-06-05
RS53964B1 (en) 2015-08-31
PL2691413T3 (pl) 2015-05-29
KR20140071958A (ko) 2014-06-12
CA2830831C (en) 2020-03-10
US9090657B2 (en) 2015-07-28
AU2012235961A1 (en) 2013-10-10
JP2014514290A (ja) 2014-06-19
EP2691413A1 (en) 2014-02-05
ES2533438T3 (es) 2015-04-10
KR20140057481A (ko) 2014-05-13
KR101868084B1 (ko) 2018-06-18
ZA201307231B (en) 2015-05-27
CA2830831A1 (en) 2012-10-04
CN103619869A (zh) 2014-03-05
MY170637A (en) 2019-08-21
EA201391396A1 (ru) 2014-02-28
EA023907B1 (ru) 2016-07-29
MX345351B (es) 2017-01-26
PL2691412T3 (pl) 2015-08-31
SG193569A1 (en) 2013-11-29
HRP20150184T1 (hr) 2015-05-08
AU2012235880B2 (en) 2016-11-17
TW201300398A (zh) 2013-01-01
JO3063B1 (ar) 2017-03-15

Similar Documents

Publication Publication Date Title
EA201391399A1 (ru) Макроциклическое соединение и способы его получения
EA201492205A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
EA201390822A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
EA201492209A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
EA201492188A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
EA201290575A1 (ru) Ингибиторы вирусов flaviviridae
EA201590215A1 (ru) Макроциклические пурины для лечения вирусных инфекций
EA201290576A1 (ru) Ингибиторы вирусов flaviviridae
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
EA201390274A1 (ru) Борсодержащие малые молекулы
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201290880A1 (ru) Новые соединения - ингибиторы фермента
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
EA201591024A1 (ru) Димерные соединения
EA201490643A1 (ru) Новые производные бетулиновой кислоты с противовирусной активностью
MX2014001623A (es) Uso de la cardiotofina-1 para el tratamiento de enfermedades renales.
PH12015500399A1 (en) Azaindolines
EA201390925A1 (ru) Производные санглиферина и способы их получения
EA201401277A1 (ru) Соединения метантиона, обладающие противовирусной активностью
EA201270786A1 (ru) α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА
TR201110248A2 (tr) 3,7-Bis(2-hydroxyethyl) icaritin bileşeninin gribal enfeksiyon tedavisinde kullanımı.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ RU